While the mechanism was not elucidated, it was hypothesised that the decrease in vascular function was either the direct result of vascular cell death via the accumulation of doxorubicin within the TME [163], or a secondary effect arising from the reduction in VEGF with the death of tumour cells. This evidence concerns the gene VEGFA and neoplasm.